The Therapy Intensity Level scale for traumatic brain injury: clinimetric assessment on neuro-monitored patients across 52 European intensive care units

Shubhayu Bhattacharyay[1,2,*], Erta Beqiri[3], Patrick Zuercher[4], Lindsay Wilson[5], Ewout W Steyerberg[6], David W Nelson[7], Andrew I R Maas[8,9], David K Menon[1], Ari Ercole[1,10], and the CENTER-TBI investigators and participants[†]

[1]Division of Anaesthesia, University of Cambridge, Cambridge, United Kingdom.
[2]Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
[3]Brain Physics Laboratory, Division of Neurosurgery, University of Cambridge, Cambridge, United Kingdom.
[4]Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.
[5]Division of Psychology, University of Stirling, Stirling, United Kingdom.
[6]Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
[7]Department of Physiology and Pharmacology, Section for Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden.
[8]Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium.
[9]Department of Translational Neuroscience, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium.
[10]Cambridge Centre for Artificial Intelligence in Medicine, Cambridge, United Kingdom.

*Corresponding author: sb2406@cam.ac.uk (SB)
[†]A full list of the CENTER-TBI investigators and participants are listed after the acknowledgements.

Running title: Assessment of the Therapy Intensity Level scale

Keywords: traumatic brain injury, therapy intensity level, intracranial pressure, intensive care unit, clinimetrics

Shubhayu Bhattacharyay	sb2406@cam.ac.uk +44 (0)1223 217889 Division of Anaesthesia, University of Cambridge, Box 93, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, United Kingdom
Erta Beqiri	vb391@cam.ac.uk +44 (0)7912 138171 Brain Physics Lab, Division of Neurosurgery, University of Cambridge, Box 167, Level A4, A Block, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, United Kingdom
Patrick Zuercher	patrick.zuercher@insel.ch +41 31 664 15 77 Department of Intensive Care Medicine, Inselspital,

Bern University Hospital, University of Bern,
Freiburgstrasse 18,
CH-3010 Bern, Switzerland

Lindsay Wilson l.wilson@stir.ac.uk
+44 (0)1786 473171
Division of Psychology,
Faculty of Natural Sciences,
University of Stirling,
Stirling FK9 4LA, United Kingdom

Ewout W Steyerberg e.w.steyerberg@lumc.nl
+31 (0)71 5269700
Dept of Biomedical Data Sciences, Leiden University Medical Center,
Leiden, The Netherlands

David W Nelson david.nelson@regionstockholm.se
+46 812379168
Function Perioperative medicine and Intensive Care (PMI),
Karolinska University Hospital, Solna,
17176 Stockholm, Sweden

Andrew I R Maas andrew.maas@uza.be
+32 38214632
Department of Neurosurgery, Antwerp University Hospital,
Drie Eikenstraat 655, 2650 Edegem, Belgium

David K Menon dkm13@cam.ac.uk
+44 (0)1223 217889
Division of Anaesthesia, University of Cambridge,
Box 93, Addenbrooke's Hospital,
Hills Road,
Cambridge CB2 0QQ, United Kingdom

Ari Ercole ae105@cam.ac.uk
+44 (0)1223 217889
Division of Anaesthesia, University of Cambridge,
Box 93, Addenbrooke's Hospital,
Hills Road,
Cambridge CB2 0QQ, United Kingdom

34

ABSTRACT

Intracranial pressure (ICP) data from traumatic brain injury (TBI) patients in the intensive care unit (ICU) cannot be interpreted appropriately without accounting for the effect of administered therapy intensity level (TIL) on ICP. A 15-point scale was originally proposed in 1987 to quantify the hourly intensity of ICP-targeted treatment. This scale was subsequently modified – through expert consensus – during the development of TBI Common Data Elements to address statistical limitations and improve usability. The latest, 38-point scale (hereafter referred to as TIL) permits integrated scoring for a 24-hour period and has a five-category, condensed version ($TIL^{(Basic)}$) based on qualitative assessment. Here, we perform a total- and component-score analysis of TIL and $TIL^{(Basic)}$ to: (1) validate the scales across the wide variation in contemporary ICP management, (2) compare their performance against that of predecessors, and (3) derive guidelines for proper scale use. From the observational Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) study, we extract clinical data from a prospective cohort of ICP-monitored TBI patients (*n*=873) from 52 ICUs across 19 countries. We calculate daily TIL and $TIL^{(Basic)}$ scores (TIL_{24} and $TIL^{(Basic)}_{24}$, respectively) from each patient's first week of ICU stay. We also calculate summary TIL and $TIL^{(Basic)}$ scores by taking the first-week maximum (TIL_{max} and $TIL^{(Basic)}_{max}$) and first-week median (TIL_{median} and $TIL^{(Basic)}_{median}$) of TIL_{24} and $TIL^{(Basic)}_{24}$ scores for each patient. We find that, across all measures of construct and criterion validity, the latest TIL scale performs significantly greater than or similarly to all alternative scales (including $TIL^{(Basic)}$) and integrates the widest range of modern ICP treatments. TIL_{median} outperforms both TIL_{max} and summarised ICP values in detecting refractory intracranial hypertension (RICH) during ICU stay. The RICH detection thresholds which maximise the sum of sensitivity and specificity are $TIL_{median}\geq 7.5$ and $TIL_{max}\geq 14$. The TIL_{24} threshold which maximises the sum of sensitivity and specificity in the detection of surgical ICP control is $TIL_{24}\geq 9$. The median scores of each TIL component therapy over increasing TIL_{24} reflect a credible staircase approach to treatment intensity escalation, from head positioning to surgical ICP control, as well as considerable variability in the use of cerebrospinal fluid drainage and decompressive craniectomy. Since $TIL^{(Basic)}_{max}$ suffers from a strong statistical ceiling effect and only covers 17% (95% CI: 16–18%) of the information in TIL_{max}, $TIL^{(Basic)}$ should not be used instead of TIL for rating maximum treatment intensity. $TIL^{(Basic)}_{24}$ and $TIL^{(Basic)}_{median}$ can be suitable replacements for TIL_{24} and TIL_{median}, respectively (with up to 33% [95% CI: 31–35%] information coverage) when TIL assessment is infeasible. Accordingly, we derive numerical ranges for categorising TIL_{24} scores into $TIL^{(Basic)}_{24}$ scores. In conclusion, our results validate TIL across a spectrum of ICP management and monitoring approaches. TIL is a more sensitive surrogate for pathophysiology than ICP and thus can be considered an intermediate outcome after TBI.

MAIN TEXT

Introduction

Elevated intracranial pressure (ICP) following traumatic brain injury (TBI) may impede the potential recovery of injured brain tissue and damage initially unaffected brain regions.[1] Therefore, for TBI patients admitted to the intensive care unit (ICU), clinicians often monitor ICP and apply a wide range of ICP-reducing treatments.[2] The selective use of these treatments typically follows a staircase approach, in which therapeutic intensity – defined by the risk and complexity of each treatment – is incrementally escalated until adequate ICP control is achieved.[3–5] Thus, therapeutic intensity must be considered when interpreting ICP. Even if two TBI patients have comparable ICP values, a difference in the intensity of their ICP-directed therapies likely indicates a difference in pathophysiological severity.

Several versions of the Therapy Intensity Level (TIL) scale have been developed to rate and compare the overall intensity of ICP management amongst TBI patients. TIL scales assign a relative intensity score to each ICP-targeting therapy and return either the sum or the maximum value of the scores of simultaneously applied therapies. In 1987, Maset *et al.* produced the original, 15-point TIL scale ($TIL^{(1987)}$) to be assessed once every four hours.[6] In 2006, Shore *et al.* published the 38-point Paediatric Intensity Level of Therapy (PILOT) scale,[7] revising $TIL^{(1987)}$ to: (1) represent updated paediatric TBI management practices, (2) have a more practical, daily assessment frequency, and (3) resolve a statistical ceiling effect. In 2011, the interagency TBI Common Data Elements (CDE) scheme developed the most recent, 38-point TIL scale (hereafter referred to as TIL) as well as a condensed, five-category $TIL^{(Basic)}$ scale through expert consensus.[8] The TIL scale revised PILOT to integrate additional ICP-directed therapies and to be applicable to adult TBI management. Moreover, $TIL^{(Basic)}$ was proposed as a simple, categorical measure to use when full TIL assessment would be infeasible. Since Zuercher *et al.* reported the validity and reliability of TIL in a two-centre cohort (n=31) in 2016,[9] the scale has become a popular research metric for quantifying ICP treatment intensity.[10–13]

However, several critical questions regarding TIL remain unanswered. It is uncertain whether the validity of TIL, reported in a relatively small population, can be generalised across the wide variation of ICP management, monitoring, and data acquisition (i.e., intermittent chart recording or high-resolution storage[14]) strategies practised in contemporary intensive care.[11,12,15,16] Furthermore, the scoring configuration of TIL has never been tested against alternatives (e.g., $TIL^{(1987)}$ and PILOT), and the relative contribution of TIL's component therapies towards the total score is unknown. It is unclear how $TIL^{(Basic)}$ numerically relates to TIL and if the former captures the essential information of the latter. In this work, we aimed to answer these questions by performing a comprehensive assessment of TIL on a large, contemporary population of ICP-monitored TBI patients across European ICUs.

Materials and Methods

Therapy intensity level (TIL) and alternative scales

TIL refers to the 38-point scale developed by the CDE scheme for TBI.[8] The domain or construct (i.e., targeted concept of a scale) of TIL is the therapeutic intensity of ICP management. The TIL scale has twelve items, each representing a distinct ICP-targeting treatment from one of eight modalities, as defined in Table 1. TIL was developed by an international expert panel which discussed: (1) the relevant ICP-treatment modalities of modern intensive care, (2) the relative risk and efficacy of individual therapies to derive scores, and (3) practical and statistical limitations of previous TIL scores.[8] In this way, TIL is a formative measurement model, in which the construct (i.e., ICP treatment intensity) is not unidimensional but rather defined by the combination of items (i.e., ICP-targeting treatments).[17] TIL was shown to have high interrater and intrarater reliability by Zuercher *et al*.[9] If a decompressive craniectomy was performed as a last resort for refractory intracranial hypertension, its score was included in the day of the operation and in every subsequent day of ICU stay. TIL scores can be calculated as frequently as clinically desired. For our analysis, we calculated the following TIL scores from the first seven days of ICU stay:

- TIL_{24}, the daily TIL score based on the sum of the highest scores per item per calendar day,
- TIL_{max}, the maximum TIL_{24} over the first week of a patient's ICU stay,
- TIL_{median}, the median TIL_{24} over the first week of a patient's ICU stay.

We also calculated scores from four other therapeutic intensity scales to compare with TIL scores. The 21-point, unweighted TIL (uwTIL) scale replaces each sub-item score in TIL with its ascending rank index (i.e., 1, 2, 3, …) within each item (Table 1). The five-category $TIL^{(Basic)}$ was also developed by the CDE scheme for TBI and takes the maximum score, from zero (i.e., no ICP-related intervention) to four, amongst all included sub-items over the calendar day.[8] We adapted the 38-point PILOT[7] and 15-point $TIL^{(1987)}$ scales[6] with minor adjustments to fit the items of TIL with a daily assessment frequency. PILOT was also shown to have high interrater and intrarater reliability by Shore *et al*.[7] For the four alternative scales, daily (i.e., $uwTIL_{24}$, $TIL^{(Basic)}{}_{24}$, $PILOT_{24}$, and $TIL^{(1987)}{}_{24}$), maximum (i.e., $uwTIL_{max}$, $TIL^{(Basic)}{}_{max}$, $PILOT_{max}$, and $TIL^{(1987)}{}_{max}$), and median (i.e., $uwTIL_{median}$, $TIL^{(Basic)}{}_{median}$, $PILOT_{median}$, and $TIL^{(1987)}{}_{median}$) scores were calculated in the same way as TIL_{24}, TIL_{max}, and TIL_{median}, respectively.

Study design and populations

Our study population was prospectively recruited for the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) core and high-resolution studies. CENTER-TBI is a longitudinal, observational cohort study (NCT02210221) involving 65 medical centres across 18 European countries and Israel. Patients were recruited between 19 December 2014 and 17 December 2017 if they met the following criteria: (1) presentation within 24 hours of a TBI, (2) clinical indication for a CT scan, and (3) no severe pre-existing neurological disorder. In accordance with

relevant laws of the European Union and the local country, ethical approval was obtained for each site, and written informed consent by the patient or legal representative was documented electronically. The list of sites, ethical committees, approval numbers, and approval dates can be found online: https://www.center-tbi.eu/project/ethical-approval. The project objectives and design of CENTER-TBI have been described in detail previously.[18,19]

In this work, we applied the following inclusion criteria in addition to those of CENTER-TBI (Fig. 1): (1) primary admission to the ICU, (2) at least 16 years old at ICU admission, (3) invasive ICP monitoring, (4) no decision to withdraw life-sustaining therapies (WLST) on the first day of ICU stay, and (5) daily assessment of TIL.

For our sub-studies evaluating the association between TIL and ICP-derived values, we created two sub-populations based on the type of ICP values available. Patients with end-hour ICP (ICP_{EH}) values, which were recorded by clinicians at the end of every other hour, constituted the TIL-ICP_{EH} sub-population. Patients with high-resolution ICP values (ICP_{HR}), which were automatically stored with monitoring software, constituted the TIL-ICP_{HR} sub-population. All patients in the TIL-ICP_{HR} sub-population were also members of the TIL-ICP_{EH} sub-population (Fig. 1).

Data collection

Data for the CENTER-TBI study was collected through the QuesGen electronic case report form system (QuesGen Systems Inc, Burlingame, CA, USA) hosted on the International Neuroinformatics Coordinating Facility (INCF) platform (INCF, Stockholm, Sweden). All data for the validation populations, except high-resolution signals, were extracted from the CENTER-TBI core study[19] (v3.0, ICU stratum) using Opal database software.[20]

ICP management data for TIL calculation

Since TIL_{24} was found to be a reliable summary of hourly TIL,[9] clinical data pertinent to the component items of TIL (i.e., ICP-guided treatments, Table 1) were recorded daily through the first week of ICU stay. We extracted all daily TIL item values for our population, and calculated TIL_{24}, $uwTIL_{24}$, $TIL^{(Basic)}_{24}$, $PILOT_{24}$, and $TIL^{(1987)}_{24}$ as defined in Table 1. For patients who underwent WLST after the first day of ICU stay, we only extracted TIL item information from before the documented date of WLST decision.

ICP_{EH} and related values

End-hour ICP (ICP_{EH}), systolic blood pressure (SBP_{EH}), and diastolic blood pressure (DBP_{EH}) were recorded by clinicians every two hours for the TIL-ICP_{EH} sub-population. Mean arterial pressure (MAP_{EH}) was calculated as $MAP_{EH} = (SBP_{EH} + 2DBP_{EH})/3$, and cerebral perfusion pressure (CPP_{EH}) was calculated as $CPP_{EH} = MAP_{EH} – ICP_{EH}$. From ICP_{EH} and CPP_{EH}, we calculated the following values:

- ICP_{24} or CPP_{24}, the mean ICP or CPP value over a calendar day of ICU stay,
- ICP_{max} or CPP_{min}, the maximum ICP_{24} or minimum CPP_{24} value over the first week of a patient's ICU stay,
- ICP_{median} or CPP_{median}, the median ICP_{24} or CPP_{24} value over the first week of a patient's ICU stay.

ICP_{HR} and related values

High-resolution signals were collected using either ICM+ software (Cambridge Enterprise Ltd, Cambridge, UK; http://icmplus.neurosurg.cam.ac.uk), Moberg CNS monitor (Moberg Research Inc, Ambler, PA, USA; https://www.moberg.com), or both. Blood pressure was obtained through arterial lines connected to pressure transducers. High-resolution ICP (ICP_{HR}) was acquired from either an intraparenchymal strain gauge probe (Codman ICP MicroSensor, Codman & Shurtleff Inc, Raynham, MA, USA), a parenchymal fibre optic pressure sensor (Camino ICP Monitor, Integra Life Sciences, Plainsboro, NJ, USA; https://www.integralife.com/), or an external ventricular drain. Detailed data collection and pre-processing methods (i.e., artefact cleaning and down-sampling to ten-second averaged time series) applied to high resolution signals in our study have been described previously.[21] Ten-second averaged ICP (ICP_{HR_10sec}) and CPP (CPP_{HR_10sec}) time-series were retrieved for this analysis, and, from ICP_{HR_10sec} and CPP_{HR_10s}, we calculated ICP_{24}/CPP_{24}, ICP_{max}/CPP_{min}, and ICP_{median}/CPP_{median} as described above.

Physician impressions

Attending ICU physicians were asked to record their daily concerns with the patient's ICP and CPP, separately, on a scale from one (not concerned) to ten (most concerned). Moreover, on each patient's ICU discharge summary, physicians were asked to record whether the patient experienced refractory intracranial hypertension during his or her ICU stay. Refractory intracranial hypertension was defined as recurrent, sustained (i.e., of at least ten minutes) increases of ICP above 20 mmHg despite medical ICP management. We extracted the daily ICP/CPP concern ratings and refractory intracranial hypertension impressions which coincided with the ICU stays of our population.

Baseline characteristics, prognosis, and outcome

We extracted baseline demographic characteristics, Marshall CT classifications,[22] and Glasgow Coma Scale (GCS)[23] scores from ICU admission.[24] We also extracted Glasgow Outcome Scale – Extended (GOSE) functional outcome scores at six months post-injury,[25] with imputation of missing values as previously described.[26] Finally, we extracted ordinal functional outcome prognosis scores, calculated from a tokenised embedding of all available clinical information in the first 24 hours of ICU stay, as described previously.[27]

Validation

We appraised the validity of TIL according to recommendations of best practice from clinimetric literature.[28] Based on the identified domain of TIL, we evaluated the construct and criterion validities of TIL. Our qualitative and quantitative assessments of TIL were performed against those of alternative scoring configurations (Table 1) for comparison.

Construct validity

Construct validity is the extent to which a clinical scale matches expectations of associations with parameters within or outside the identified domain. Construct validity is further broken down into convergent validity (i.e., associations with similar constructs), discriminant validity (i.e., associations with divergent constructs), and differentiation by known groups. In this work, statistical associations between study variables were measured with:

- Spearman's correlation coefficients (ρ) for static (i.e., measured once) variables,
- repeated measures correlation coefficients (r_{rm})[29] – interpreted as within-individual strength of association – for longitudinal (i.e., measured over time) variables,
- linear mixed effects regression (LMER) coefficients (β_{LMER}) of daily scale scores (e.g., TIL_{24}) when regressing ICP_{24} or CPP_{24} on daily scale scores and the day of ICU stay (Day_{ICU}), accounting for inter-patient variability with random intercepts. Therefore, β_{LMER} were interpreted as the expected difference in ICP_{24} or CPP_{24} per unit increase of daily scale score, independent of time since ICU admission or inter-patient variation.

For convergent validity, we expected therapeutic intensity to correlate at least mildly (i.e., $|\rho|\geq 0.2$, $|r_{rm}|\geq 0.2$, $|\beta_{LMER}|>0$) with markers of injury severity (i.e., baseline GCS and baseline outcome prognoses), functional outcome (i.e., six-month GOSE), clinical concerns of ICP status, and ICP itself. Accordingly, we calculated: (1) ρ values between TIL_{max} and GCS, ordinal prognosis scores, GOSE, and ICP_{max}, (2) ρ values between TIL_{median} and GCS, ordinal prognosis scores, GOSE, and ICP_{median}, (3) r_{rm} values between TIL_{24} and physician concern of ICP and ICP_{24}, and (4) β_{LMER} of TIL_{24} when regressing ICP_{24} on Day_{ICU} and TIL_{24} (i.e., ICP_{24}~Day_{ICU}+TIL_{24}), accounting for inter-patient variability with random intercepts.

For discriminant validity, we expected therapeutic intensity to be more strongly correlated with ICP and physician concerns of ICP than with CPP and physician concerns of CPP, respectively. Even though CPP control through fluid loading or vasopressor therapy is a component modality of TIL (Table 1), we expected TIL to capture ICP management (i.e., the construct) more accurately than CPP management. We compared: (1) ρ values of TIL_{max} vs. CPP_{min} to those of TIL_{max} vs. ICP_{max}, (2) ρ values of TIL_{median} vs. CPP_{median} to those of TIL_{median} vs. ICP_{median}, (3) r_{rm} values of TIL_{24} vs. CPP_{24} to those of TIL_{24} vs. ICP_{24}, and (4) the β_{LMER} of TIL_{24} when regressing CPP_{24}~Day_{ICU}+TIL_{24} to the β_{LMER} of TIL_{24} when regressing ICP_{24}~Day_{ICU}+TIL_{24}.

For differentiation by known groups, we expected TIL_{max} and TIL_{median} to effectively discriminate patients who experienced refractory intracranial hypertension during ICU stay from those who did not. We calculated the area under the receiver operating

characteristic curve (AUC), which, in our case, was interpreted as the probability of a randomly selected patient with refractory intracranial hypertension having a higher TIL_{max} or TIL_{median} score than one without it. We also compared the AUCs of TIL_{max} and TIL_{median} to ICP_{max} and ICP_{median} and determined the sensitivity and specificity of refractory intracranial hypertension detection at each threshold of TIL_{max} and TIL_{median}.

Criterion validity

Criterion (or concurrent) validity is the degree to which there is an association between a clinical scale and other scales measuring the same construct, particularly a gold standard assessment. Since there is no extant "gold standard" for assessing ICP management intensity, we tested the concurrent criterion validity of TIL by calculating its associations with its predecessors (i.e., PILOT and $TIL^{(1987)}$), mindful of their limitations as described above. More specifically, we calculated: (1) ρ values between TIL_{max} and prior scale maximum scores (i.e., $PILOT_{max}$ and $TIL^{(1987)}{}_{max}$), (2) ρ values between TIL_{median} and prior scale median scores (i.e., $PILOT_{median}$ and $TIL^{(1987)}{}_{median}$), and (3) r_{rm} between TIL_{24} and prior scale daily scores (i.e., $PILOT_{24}$ and $TIL^{(1987)}{}_{24}$).

Component item analysis

We evaluated inter-item (i.e., inter-treatment) and adjusted item-total associations of TIL_{24}, $uwTIL_{24}$, $PILOT_{24}$, and $TIL^{(1987)}{}_{24}$ by calculating r_{rm} values. Item-total correlations were adjusted by subtracting the tested item score from the total score prior to calculating the correlation. We measured Cronbach's alpha (α) to assess internal reliability amongst scale items at each day of ICU stay. Moreover, we calculated the median score contribution of each item per total TIL_{24} score. The association between each TIL_{24} item score and ICP_{24}, CPP_{24}, physician concern of ICP, and physician concern of CPP was calculated with r_{rm} values. Finally, we trained LMER models regressing ICP_{24} and CPP_{24} on all TIL items (with categorical dummy encoding) and Day_{ICU} concurrently. The β_{LMER} values from these models were interpreted as the average change in ICP_{24} or CPP_{24} associated with each treatment when accounting for all other ICP-guided treatments, time since ICU admission, and inter-patient variability with random intercepts.

$TIL^{(Basic)}$ information coverage

We examined the distributions of $TIL^{(Basic)}{}_{24}$ per TIL_{24} and TIL_{24} per $TIL^{(Basic)}{}_{24}$ to derive thresholds for categorising TIL_{24} into $TIL^{(Basic)}{}_{24}$. We also calculated the information coverage (IC) of $TIL^{(Basic)}$ by dividing the mutual information (MI) of $TIL^{(Basic)}$ and TIL by the entropy of TIL. IC was calculated with $TIL^{(Basic)}{}_{24}$ and TIL_{24} for days one through seven of ICU stay, with $TIL^{(Basic)}{}_{max}$ and TIL_{max}, and with $TIL^{(Basic)}{}_{median}$ and TIL_{median}.

Statistical analysis

Multiple imputation of missing values

Five of the static study variables had missing values for some of the patients in our study: GCS, GOSE, baseline prognosis scores, Marshall CT classifications, and refractory intracranial hypertension status. We assessed the patterns of missingness (Supplementary Fig. S1) and multiply imputed (m=100) these variables with independent, stochastic predictive mean matching functions using the *mice* package[30] (v3.9.0) in R (v4.2.3). We assumed these variables to be missing-at-random (MAR) (as previously reported on CENTER-TBI data[31]) and supported this assumption by training imputation models on all study measures as well as correlated auxiliary variables (e.g., raised ICP during ICU stay).

For daily longitudinal study variables, we considered a value to be missing if the patient was still in the ICU and WLST had not been decided on or before that day. We assessed the longitudinal patterns of missingness (Supplementary Fig. S2) and multiply imputed (m=100) these variables with the multivariate, time-series algorithm from the *Amelia II* package[32] (v1.7.6) in R over the first week of ICU stay. The algorithm exploits both between-variable and within-variable correlation structures over time to stochastically impute missing time series values in independently trained runs. We validated the MAR assumption by identifying characteristics significantly associated with longitudinal variable missingness (Supplementary Table S1) and included auxiliary information associated with value missingness (e.g., reasons for stopping ICP monitoring) in the imputation model.

Statistical inference

We calculated 95% confidence intervals (CI) for ρ, r_{rm}, β_{LMER}, AUC, sensitivity, specificity, α, and IC values using bootstrapping with 1,000 resamples of unique patients. For each resample, one of the 100 missing value imputations was randomly chosen. Therefore, confidence intervals represented the uncertainty due to patient resampling and missing value imputation.

Code

All statistical analyses were performed in Python (v3.8.2) or R, and all visualisations were created in R. All scripts used in this study are publicly available on GitHub: https://github.com/sbhattacharyay/CENTER-TBI_TIL.

Results

Study population

Of the 4,509 patients available for analysis in the CENTER-TBI core study, 873 patients from 52 ICUs met the additional inclusion criteria of this work. Amongst them, 837

constituted the TIL-ICP_{EH} sub-population and 259 constituted the TIL-ICP_{HR} sub-population (Fig. 1). Summary characteristics of the overall population as well as those of the TIL-ICP_{EH} and TIL-ICP_{HR} sub-populations are detailed in Table 2. Apart from two of the prognosis scores pertaining to the probability of returning to pre-injury life roles (i.e., Pr(GOSE>5) and Pr(GOSE>6)), none of the tested characteristics were significantly different between patients in the TIL-ICP_{HR} sub-population and those outside of it (Table 2).

The median ICU stay duration of our population was 14 days (IQR: 7.8–23 days), and 83% (n=726) stayed through at least seven calendar days. At each day of ICU stay, less than 2.4% of the expected TIL scores were missing (Supplementary Fig. S2). Each TIL component item (Table 1) is represented by at least 17% (n=147, intracranial surgery) and each sub-item is represented by at least 4.9% (n=43, high-dose mannitol) of the population (Supplementary Table S2). The distributions of TIL_{max}, TIL_{median}, and TIL_{24}, juxtaposed against the scores of alternative scales (Table 1), are displayed in Fig. 2. The distributions of TIL and PILOT were visually similar, and $TIL^{(Basic)}_{max}$ had a strong ceiling effect (i.e., 57% of the population had the maximum score). Whilst there was no significant difference in TIL_{24} distribution over the first seven days, most patients had their highest TIL_{24} (i.e., TIL_{max}) soon after ICU admission (median: day two, IQR: days one–three). The Spearman's rank correlation coefficient (ρ) between TIL_{max} and TIL_{median} was 0.80 (95% CI: 0.77–0.82), and the median TIL_{median}:TIL_{max} ratio was 0.65 (IQR: 0.45–0.80).

Validation of TIL

The 95% CIs of ρ values, repeated measures correlation coefficients (r_{rm}), and linear mixed effect regression coefficients (β_{LMER}) of TIL with other study measures are visualised in Fig. 3. Both TIL_{max} and TIL_{median} had mildly negative correlations ($-0.26<\rho_{mean}<-0.19$) with baseline GCS, six-month GOSE, and functional outcome prognoses (Fig. 3A–B). The within-individual association of TIL_{24} with physician concerns of ICP was moderately positive (r_{rm}=0.35 [95% CI: 0.31–0.38]) and significantly higher than that of $TIL^{(Basic)}_{24}$ (Fig. 3C). The association between ICP_{median} and TIL_{median} was moderately positive ($0.35<\rho_{mean}<0.45$) with both ICP_{EH} and ICP_{HR} values, and the association between ICP_{max} and TIL_{max} was moderately positive (ρ=0.41 [95% CI: 0.33–0.46]) with ICP_{EH} values. The ICP_{max} vs. TIL_{max} correlation was not significant (ρ=0.01 [95% CI: -0.16–0.17]) with ICP_{HR} values; however, without imputing missing ICP_{HR} values, the ρ was 0.43 (95% CI: 0.35–0.50). This suggests that the longitudinal missingness of ICP_{HR} (Supplementary Fig. S2) for our sample size made the ICP_{max} estimation significantly imprecise. Additionally, the within-individual association with ICP_{24} was either weak or not significant for any daily scale score according to r_{rm} (Fig. 3C) and β_{LMER} (Fig. 3D) values. On average, a single point increase in TIL_{24} was associated with a 0.22 (95% CI: 0.15–0.30) mmHg increase in daily mean ICP_{EH} and a 0.19 (95% CI: -0.06–0.43) mmHg increase in daily mean ICP_{HR}. These results mostly affirm the convergent validity of TIL but highlight the broad intra-patient variability between ICP and therapeutic intensity. From the distribution of ICP_{24} values at each TIL_{24} score (Fig. 4A), we observed both considerable ICP_{24} overlap across each TIL_{24} score and an overall positive relationship between TIL_{24} and ICP_{24}, particularly for $TIL_{24}\geq 8$.

The correlation between TIL and both prior scales (i.e., PILOT and $TIL^{(1987)}$) was positively strong for maximum, median, and daily scores (Supplementary Fig. S3), establishing the criterion validity of TIL. According to 95% CIs, the association of TIL with prior scales was stronger than that of uwTIL or $TIL^{(Basic)}$ (Supplementary Fig. S3).

According to ρ, r_{rm}, and β_{LMER} values (Fig. 3), the associations of TIL with CPP and of TIL with physician concerns of CPP were weaker than or not significantly different from the corresponding associations with ICP. Moreover, the trend of CPP_{24} distributions over different TIL_{24} scores is not as visually apparent as that of ICP_{24} distributions over different TIL_{24} scores (Fig. 4B). These results support the discriminant validity of TIL.

In our population, 157 patients (18% of 864 assessed) were reported to experience refractory intracranial hypertension during ICU stay. TIL_{max} correctly discriminated these patients from the others 81% (95% CI: 78–84%) of the time (Fig. 5A), and TIL_{median} did so 83% (95% CI: 80–86%) of the time (Fig. 5B). This performance of TIL was significantly greater than or similar to that of all alternative scales (Fig. 5A–B). Furthermore, TIL_{median} had significantly greater discrimination performance than ICP_{max} (Fig. 5C) and ICP_{median} (Fig. 5D), respectively. The sensitivity and specificity of refractory intracranial hypertension detection at each threshold of TIL_{max}, TIL_{median}, $TIL^{(Basic)}{}_{max}$, and $TIL^{(Basic)}{}_{median}$ are listed in Supplementary Table S3 and visualised in Fig. 5C–D. The thresholds which maximised the sum of sensitivity and specificity were $TIL_{max}\geq 14$ (sensitivity: 68% [95% CI: 62–74%], specificity: 79% [95% CI: 77–81%]) and $TIL_{median}\geq 7.5$ (sensitivity: 81% [95% CI: 77–87%], specificity: 72% [95% CI: 70–75%]) (Table 3).

TIL component items

Whilst there was wide variation in item combinations per TIL_{24} score (i.e., sum of median scores was often under diagonal line in Fig. 6A), the average order of therapeutic escalation was fairly consistent: position, sedation, CPP management, ventilatory management, neuromuscular blockade, hyperosmolar therapy, temperature control, and then surgery for refractory ICP. Surgical control of ICP occurred in over 50% of reported cases at each TIL_{24} above 18 (Fig. 6A), but the threshold which maximised the sum of sensitivity and specificity in detecting surgical ICP control was $TIL_{24}\geq 9$ (Table 3, performance at each threshold is listed in Supplementary Table S4). The inter-item r_{rm} values of TIL_{24} (Supplementary Fig. S4) were mostly positive except for cerebrospinal fluid (CSF) drainage, which did not correlate significantly with most other items, and decompressive craniectomy, which did not correlate significantly with CSF, ventilatory, or temperature control. Consistent with Fig. 6A, this result suggested that CSF drainage and decompressive craniectomy were the most variably applied therapies across study ICUs. The Cronbach's alpha (α) value of TIL_{24} was, at best, 0.65 (95% CI: 0.62–0.68) and lower (albeit, not significantly) than that of $uwTIL_{24}$ at each day of ICU stay (Supplementary Fig. S5). However, since TIL is a formative scale (i.e., the construct is multidimensional and defined by the items), high inter-item correlation and α values are not necessary for item validation.[17] Amongst all TIL_{24} items, sedation was most strongly correlated with adjusted TIL_{24} scores and physician concerns of ICP (Fig. 6B). From $10\leq TIL_{24}\leq 20$, a plateau effect

of high-dose sedation combined with neuromuscular blockade was observed in most cases (Fig. 6A). When accounting for all other TIL_{24} sub-items, time since ICU admission, as well as inter-patient variability, ventilation, mannitol administration, and hypertonic saline administration were most strongly associated with ICP_{24} and vasopressors were most strongly associated with CPP_{24} (Fig. 6C).

$TIL^{(Basic)}$

Based on the median $TIL^{(Basic)}_{24}$ score at each TIL_{24} score (Fig. 7A), we derived the ranges for mapping TIL_{24} onto $TIL^{(Basic)}_{24}$ in Table 3. There is, however, considerable overlap of TIL_{24} scores across $TIL^{(Basic)}_{24}$ scores (Fig. 7B), particularly in the range of $6 \leq TIL_{24} \leq 10$. $TIL^{(Basic)}_{24}=3$ was not the most represented score at any TIL_{24} score (Fig. 7A). $TIL^{(Basic)}_{24}$ covered up to 33% (95% CI: 31–34%) of the information (i.e., entropy) in TIL_{24}, and $TIL^{(Basic)}_{median}$ covered up to 28% (95% CI: 27–30%) of the information in TIL_{median} (Fig. 7C). $TIL^{(Basic)}_{max}$ only covered 17% (95% CI: 16–18%) of the information in TIL_{max} (Fig. 7C).

Discussion

In this work, we performed a large-scale (*n*=873), multicentre (52 ICUs, 19 countries), and prospective validation study of TIL and $TIL^{(Basic)}$ against alternative scales. Our results support the validity of TIL as a metric for scoring ICP-directed therapeutic intensity. The dataset we used, as part of the CENTER-TBI study, not only reflects the modern variation in ICP-directed therapeutic intensity (Fig. 2 and Fig. 6A) but also illustrates the practical feasibility of daily TIL assessment: out of 885 eligible patients, 873 (99%) had daily TIL scores (Fig. 1) with less than 2.4% daily missingness (Supplementary Fig. S2).

We scrutinised and validated the use of TIL as a metric for scoring ICP-directed therapeutic intensity and for marking pathophysiological severity. The statistical construct and criterion validity measures of TIL were significantly greater or similar to those of alternative scales (Fig. 3 and Fig. 5), and TIL integrated the widest range of modern ICP treatments (Table 1). Summarised TIL scores outperformed summarised ICP values in detecting refractory intracranial hypertension. Our analysis yielded empirical ranges for interpreting TIL in terms of refractory intracranial hypertension, surgical intervention, and the condensed, $TIL^{(Basic)}$ scores (Table 3). On a component level (Fig. 6A), TIL_{24} reflected a pattern of treatment intensity escalation consistent with clinical algorithms[2,3,5] as well as a wide variation in treatment combinations, particularly in the use of CSF drainage and decompressive craniectomy. This finding is consistent with a previous CENTER-TBI study – which revealed inter-centre variation in TIL treatment selection and time to administration[12] – and encourages an investigation of differences in TIL and long-term outcome between centres with known differences in ICP management strategies. In summary, our results support the use of TIL as an intermediate outcome for treatment effect, as done in previous studies.[33–35]

522 Due to a strong ceiling effect (Fig. 2A and Fig. 5A), $TIL^{(Basic)}$ should not be used instead
523 of TIL for rating maximum treatment intensity. $TIL^{(Basic)}_{24}$ and TIL_{median} covered up to 33%
524 of the information in TIL_{24} (Fig. 7C), but the $TIL^{(Basic)}_{24}$ associations with physician
525 concerns of ICP were significantly worse than those of TIL_{24} (Fig. 3C). TIL should always
526 be preferred to $TIL^{(Basic)}$, but we believe daily or median $TIL^{(Basic)}$ can be a suitable
527 alternative when daily or median TIL assessment is infeasible.
528
529 Moreover, we evaluated TIL with both end-hour (ICP_{EH}) and high-resolution (ICP_{HR}) ICP
530 values. ICP_{HR}, if available, should be considered the gold standard in terms of precision
531 and granularity of the information provided, and neuromonitoring-related results from the
532 ICP_{HR} population should generally take precedence.[14] However, 67% of expected ICP_{HR}
533 values were missing on day one of ICU stay (Supplementary Fig. S2), likely due to the
534 time required to arrange high-resolution data collection. Consequently, estimates of high-
535 resolution ICP_{max} were significantly affected by missing value imputation and became
536 imprecise at our sample size (Fig. 3A). In these cases, results from the ICP_{EH} population
537 served as a valuable reference on a substantially larger sample size (Table 2) since ICP_{EH}
538 and CPP_{EH} have been shown to be fair end-hour representations of ICP_{HR} and CPP_{HR},
539 respectively, in CENTER-TBI.[14] The considerable overlap of ICP_{24} values across TIL_{24}
540 scores (both at low and high levels of ICP, Fig. 4A) and the insignificant-to-weak, within-
541 individual association between ICP_{24} and TIL_{24} (Fig. 3C–D) highlight the need to account
542 for therapeutic intensity when interpreting ICP. Additionally, the higher median ICP_{24}
543 values for $TIL_{24} \geq 8$ (Fig. 4A) may suggest that clinicians accept a slightly higher ICP when
544 balancing the risks of elevating therapeutic intensity against those of intracranial
545 hypertension.
546
547 We see three main opportunities to improve TIL. First, the item scores of TIL and its
548 predecessors (i.e., PILOT and $TIL^{(1987)}$) were not derived empirically. Data-driven
549 techniques, such as confirmatory factor analysis,[28] can be used to derive scoring
550 configurations which optimise a defined objective (e.g., maximal separation of patients).
551 However, data-driven scores do not necessarily reflect the intended construct (i.e.,
552 treatment risk and complexity),[36] and, in general, item scoring does not have an
553 appreciable impact on overall scale performance.[28] Second, the items of TIL must evolve
554 as therapeutic approaches to ICP management evolve. TIL discriminated refractory
555 intracranial hypertension status significantly better than $TIL^{(1987)}$ (Fig. 5A–B) because TIL
556 updated $TIL^{(1987)}$ with six additional items (Table 1). We recommend updating and re-
557 evaluating TIL each time ICP-treatment modalities or their perceived risks change.
558 Finally, the development of TIL was largely informed by the perspective of ICU practices
559 in high-income countries.[8] Likewise, this assessment was performed in a cohort of
560 patients across Europe and Israel. Especially given the disproportionately higher burden
561 of TBI in low- and middle-income countries,[37] it is imperative to test and, if necessary,
562 adapt TIL to a more inclusive, global population of TBI.
563
564 By design, TIL does not encompass all facets of modern intensive care for TBI patients.
565 Brain tissue oxygen tension ($PbtO_2$),[38] cerebral microdialysis,[39] and brain temperature[40]
566 have emerged as multimodal, neuromonitoring targets which may affect ICU
567 management in addition to ICP or CPP. Therefore, TIL should be interpreted not as

general treatment intensity but rather as the intensity of ICP-directed therapy specifically. We encourage the development and validation of clinical scales assessing the intensity of TBI treatments directed at other physiological targets. Since treatments for other targets often overlap with those for ICP or CPP (e.g., vasopressors target both $PbtO_2$ and CPP),[2] we also promote a consolidation of all TBI treatments in an overall therapeutic intensity scale which considers the effect of each treatment on multiple physiological targets.

We recognise several limitations of our analysis. Whilst numerous investigators assessed TIL across the study ICUs, each TIL score was only assessed once. Therefore, we could not evaluate the interrater reliability of TIL. Similarly, data needed to calculate the full TIL score was only recorded once a day, so we could not determine if a daily assessment frequency was sufficient. Since the prior TIL validation study reported a high interrater reliability and recommended a daily assessment frequency,[9] we assumed both to be true. The results from the Randomised Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of Intracranial Pressure (RESCUEicp) trial[41] – published amidst CENTER-TBI patient recruitment in 2016 – have likely changed the global frequency and perceived intensity of decompressive craniectomy for TBI. Therefore, we recognise the potentially confounding effect of the trial results on treatment decision making for some patients in the CENTER-TBI population and encourage a potential reappraisal of the therapeutic intensity of decompressive craniectomy through expert discussion and statistical validation. The physician impressions (i.e., physician concerns of ICP and CPP and refractory intracranial hypertension status) were subjective, and we did not have enough information to account for interrater variability. Therefore, these scores and labels should be considered unrefined. Finally, because of limited dosage data for numerical treatments (i.e., CSF drainage, ventilation, hyperosmolar therapy, and temperature control), we did not test alternative sub-item categorisations.

Conclusion

TIL is a valid, generalisable measurement of ICP management amongst neuro-monitored TBI patients in the ICU. On all validation metrics, TIL performs at least as well as its alternatives and considers the widest range of modern treatment strategies. TIL's component scores over increasing TIL reflect a clinically credible order of treatment escalation, from head positioning to ICP-directed surgery. $TIL^{(Basic)}$ is not suitable for evaluating maximum treatment intensity, but daily $TIL^{(Basic)}$ and median $TIL^{(Basic)}$ can cover up to a third of the information in TIL. In the setting of clinical ICP management, TIL is a more sensitive marker of pathophysiological severity than ICP and can be considered an intermediate outcome after TBI.

Transparency, Rigor and Reproducibility Summary

The CENTER-TBI study was pre-registered at clinicaltrials.gov (NCT02210221, https://clinicaltrials.gov/ct2/show/NCT02210221). The analysis plan was registered after beginning data collection but before data analysis at https://www.center-

tbi.eu/data/approved-proposals (#491), and the lead author with primary responsibility for the analysis certifies that the analysis plan was pre-specified. A sample size of 903 patients was planned based on availability of critically ill, ICP-monitored, adult TBI patients recruited for CENTER-TBI. Actual sample size was 873, as 18 patients had a documented decision to WLST on the first day of ICU stay and 12 additional patients did not have daily TIL scores assessed. A patient inclusion diagram is provided (Fig. 1). TIL scoring and clinical data entry was performed by investigators who were aware of relevant characteristics of the participants. Participants were recruited between 19 December 2014 and 17 December 2017, and data (including follow-up results) were collected until 31 March 2021. High-resolution waveforms were stored directly from bedside monitoring software, as described in the Methods and Materials. Variability amongst different TIL assessors is not expected to be significant based on the established high interrater reliability of TIL.[9] All equipment and software used to perform imaging and preprocessing are widely available from commercial sources or open source repositories. The clinimetric validation procedure and the primary clinical metric (TIL) are established standards in the field, based on previously published results[9,28] and this study. The assumption of bootstrapping-derived confidence intervals is that the sample is representative of the population. This study is, itself, an external validation, and internal replication by the study group was performed. Individual participant data are available online, conditional to approved online study proposal, with no end date at https://www.center-tbi.eu/data. Signed confirmation of a data access agreement is required, and all access must comply with regulatory restrictions imposed on the original study. All analytic code used to perform the statistical analyses are publicly available online at: https://github.com/sbhattacharyay/CENTER-TBI_TIL. This paper will be published under a Creative Commons Open Access license, and upon publication, will be freely available at https://www.liebertpub.com/loi/neu.

Acknowledgments

We are grateful to the patients and families of our study for making our efforts to improve TBI care possible. S.B. would like to thank Kathleen Mitchell-Fox (Princeton University) for offering comments on the manuscript.

Author contributions

S.B. co-conceptualised the aims, developed the methodology and design, curated, analysed, and visualised the data, acquired funding, and wrote the manuscript. E.B. curated and analysed data, acquired funding, and reviewed the manuscript. P.Z. and L.W. curated data, aided in the development of methodology, and reviewed the manuscript. EWS and DWN curated data, acquired funding, advised statistical analysis, and reviewed the manuscript. A.I.R.M. and D.K.M. curated data, acquired funding, co-conceptualised the aims, co-developed the methodology, and reviewed the manuscript. A.E. served as principal investigator, curated data, conceptualised the aims, co-developed the methodology, and reviewed the manuscript. All authors read and approved the final manuscript.

Conflicts of interest

All authors declare no financial or non-financial competing interests.

Funding statement

This research was supported by the National Institute for Health Research (NIHR) Brain Injury MedTech Co-operative. CENTER-TBI was supported by the European Union 7th Framework programme (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences Corporation (USA), and from NeuroTrauma Sciences (USA). CENTER-TBI also acknowledges interactions and support from the International Initiative for TBI Research (InTBIR) investigators. S.B. is funded by a Gates Cambridge Scholarship. E.B. is funded by the Medical Research Council (MR N013433-1) and by a Gates Cambridge Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The CENTER-TBI investigators and participants

The co-lead investigators of CENTER-TBI are designated with an asterisk (*), and their contact email addresses are listed below.

Cecilia Åkerlund[1], Krisztina Amrein[2], Nada Andelic[3], Lasse Andreassen[4], Audny Anke[5], Anna Antoni[6], Gérard Audibert[7], Philippe Azouvi[8], Maria Luisa Azzolini[9], Ronald Bartels[10], Pál Barzó[11], Romuald Beauvais[12], Ronny Beer[13], Bo-Michael Bellander[14], Antonio Belli[15], Habib Benali[16], Maurizio Berardino[17], Luigi Beretta[9], Morten Blaabjerg[18], Peter Bragge[19], Alexandra Brazinova[20], Vibeke Brinck[21], Joanne Brooker[22], Camilla Brorsson[23], Andras Buki[24], Monika Bullinger[25], Manuel Cabeleira[26], Alessio Caccioppola[27], Emiliana Calappi[27], Maria Rosa Calvi[9], Peter Cameron[28], Guillermo Carbayo Lozano[29], Marco Carbonara[27], Simona Cavallo[17], Giorgio Chevallard[30], Arturo Chieregato[30], Giuseppe Citerio[31,32], Hans Clusmann[33], Mark Coburn[34], Jonathan Coles[35], Jamie D. Cooper[36], Marta Correia[37], Amra Čović[38], Nicola Curry[39], Endre Czeiter[24], Marek Czosnyka[26], Claire Dahyot-Fizelier[40], Paul Dark[41], Helen Dawes[42], Véronique De Keyser[43], Vincent Degos[16], Francesco Della Corte[44], Hugo den Boogert[10], Bart Depreitere[45], Đula Đilvesi[46], Abhishek Dixit[47], Emma Donoghue[22], Jens Dreier[48], Guy-Loup Dulière[49], Ari Ercole[47], Patrick Esser[42], Erzsébet Ezer[50], Martin Fabricius[51], Valery L. Feigin[52], Kelly Foks[53], Shirin Frisvold[54], Alex Furmanov[55], Pablo Gagliardo[56], Damien Galanaud[16], Dashiell Gantner[28], Guoyi Gao[57], Pradeep George[58], Alexandre Ghuysen[59], Lelde Giga[60], Ben Glocker[61], Jagoš Golubovic[46], Pedro A. Gomez[62], Johannes Gratz[63], Benjamin Gravesteijn[64], Francesca Grossi[44], Russell L. Gruen[65], Deepak Gupta[66], Juanita A. Haagsma[64], Iain Haitsma[67], Raimund Helbok[13], Eirik Helseth[68], Lindsay Horton[69], Jilske Huijben[64], Peter J. Hutchinson[70], Bram Jacobs[71], Stefan Jankowski[72], Mike Jarrett[21], Ji-yao Jiang[58], Faye Johnson[73], Kelly Jones[52], Mladen Karan[46], Angelos G. Kolias[70], Erwin Kompanje[74], Daniel Kondziella[51], Evgenios Kornaropoulos[47], Lars-Owe Koskinen[75], Noémi Kovács[76], Ana

Kowark[77], Alfonso Lagares[62], Linda Lanyon[58], Steven Laureys[78], Fiona Lecky[79,80], Didier Ledoux[78], Rolf Lefering[81], Valerie Legrand[82], Aurelie Lejeune[83], Leon Levi[84], Roger Lightfoot[85], Hester Lingsma[64], Andrew I.R. Maas[43,86,*], Ana M. Castaño-León[62], Marc Maegele[87], Marek Majdan[20], Alex Manara[88], Geoffrey Manley[89], Costanza Martino[90], Hugues Maréchal[49], Julia Mattern[91], Catherine McMahon[92], Béla Melegh[93], David Menon[47,*], Tomas Menovsky[43,86], Ana Mikolic[64], Benoit Misset[78], Visakh Muraleedharan[58], Lynnette Murray[28], Ancuta Negru[94], David Nelson[1], Virginia Newcombe[47], Daan Nieboer[64], József Nyirádi[2], Otesile Olubukola[79], Matej Oresic[95], Fabrizio Ortolano[27], Aarno Palotie[96,97,98], Paul M. Parizel[99], Jean-François Payen[100], Natascha Perera[12], Vincent Perlbarg[16], Paolo Persona[101], Wilco Peul[102], Anna Piippo-Karjalainen[103], Matti Pirinen[96], Dana Pisica[64], Horia Ples[94], Suzanne Polinder[64], Inigo Pomposo[29], Jussi P. Posti[104], Louis Puybasset[105], Andreea Radoi[106], Arminas Ragauskas[107], Rahul Raj[103], Malinka Rambadagalla[108], Isabel Retel Helmrich[64], Jonathan Rhodes[109], Sylvia Richardson[110], Sophie Richter[47], Samuli Ripatti[96], Saulius Rocka[107], Cecilie Roe[111], Olav Roise[112,113], Jonathan Rosand[114], Jeffrey V. Rosenfeld[115], Christina Rosenlund[116], Guy Rosenthal[55], Rolf Rossaint[77], Sandra Rossi[101], Daniel Rueckert[61] Martin Rusnák[117], Juan Sahuquillo[106], Oliver Sakowitz[91,118], Renan Sanchez-Porras[118], Janos Sandor[119], Nadine Schäfer[81], Silke Schmidt[120], Herbert Schoechl[121], Guus Schoonman[122], Rico Frederik Schou[123], Elisabeth Schwendenwein[6], Charlie Sewalt[64], Ranjit D. Singh[102], Toril Skandsen[124,125], Peter Smielewski[26], Abayomi Sorinola[126], Emmanuel Stamatakis[47], Simon Stanworth[39], Robert Stevens[127], William Stewart[128], Ewout W. Steyerberg[64,129], Nino Stocchetti[130], Nina Sundström[131], Riikka Takala[132], Viktória Tamás[126], Tomas Tamosuitis[133], Mark Steven Taylor[20], Aurore Thibaut[78], Braden Te Ao[52], Olli Tenovuo[104], Alice Theadom[52], Matt Thomas[88], Dick Tibboel[134], Marjolein Timmers[74], Christos Tolias[135], Tony Trapani[28], Cristina Maria Tudora[94], Andreas Unterberg[91], Peter Vajkoczy[136], Shirley Vallance[28], Egils Valeinis[60], Zoltán Vámos[50], Mathieu van der Jagt[137], Gregory Van der Steen[43], Joukje van der Naalt[71], Jeroen T.J.M. van Dijck[102], Inge A. M. van Erp[102], Thomas A. van Essen[102], Wim Van Hecke[138], Caroline van Heugten[139], Ernest van Veen[64], Thijs Vande Vyvere[140], Roel P. J. van Wijk[102], Alessia Vargiolu[32], Emmanuel Vega[83], Kimberley Velt[64], Jan Verheyden[138], Paul M. Vespa[141], Anne Vik[124,142], Rimantas Vilcinis[133], Victor Volovici[67], Nicole von Steinbüchel[38], Daphne Voormolen[64], Petar Vulekovic[46], Kevin K.W. Wang[143], Daniel Whitehouse[47], Eveline Wiegers[64], Guy Williams[47], Lindsay Wilson[69], Stefan Winzeck[47], Stefan Wolf[144], Zhihui Yang[114], Peter Ylén[145], Alexander Younsi[91], Frederick A. Zeiler[47,146], Veronika Zelinkova[20], Agate Ziverte[60], Tommaso Zoerle[27]

[1]Department of Physiology and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden
[2]János Szentágothai Research Centre, University of Pécs, Pécs, Hungary
[3]Division of Clinical Neuroscience, Department of Physical Medicine and Rehabilitation, Oslo University Hospital and University of Oslo, Oslo, Norway
[4]Department of Neurosurgery, University Hospital Northern Norway, Tromso, Norway
[5]Department of Physical Medicine and Rehabilitation, University Hospital Northern Norway, Tromso, Norway
[6]Trauma Surgery, Medical University Vienna, Vienna, Austria

[7]Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy, France
[8]Raymond Poincare hospital, Assistance Publique – Hopitaux de Paris, Paris, France
[9]Department of Anesthesiology & Intensive Care, S Raffaele University Hospital, Milan, Italy
[10]Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The Netherlands
[11]Department of Neurosurgery, University of Szeged, Szeged, Hungary
[12]International Projects Management, ARTTIC, Munchen, Germany
[13]Department of Neurology, Neurological Intensive Care Unit, Medical University of Innsbruck, Innsbruck, Austria
[14]Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska University Hospital, Stockholm, Sweden
[15]NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK
[16]Anesthesie-Réanimation, Assistance Publique – Hopitaux de Paris, Paris, France
[17]Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino - Orthopedic and Trauma Center, Torino, Italy
[18]Department of Neurology, Odense University Hospital, Odense, Denmark
[19]BehaviourWorks Australia, Monash Sustainability Institute, Monash University, Victoria, Australia
[20]Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovakia
[21]Quesgen Systems Inc., Burlingame, California, USA
[22]Australian & New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
[23]Department of Surgery and Perioperative Science, Umeå University, Umeå, Sweden
[24]Department of Neurosurgery, Medical School, University of Pécs, Hungary and Neurotrauma Research Group, János Szentágothai Research Centre, University of Pécs, Hungary
[25]Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
[26]Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
[27]Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
[28]ANZIC Research Centre, Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, Australia
[29]Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain
[30]NeuroIntensive Care, Niguarda Hospital, Milan, Italy
[31]School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy
[32]NeuroIntensive Care Unit, Department Neuroscience, IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy
[33]Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen, Germany
[34]Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany

[35]Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
[36]School of Public Health & PM, Monash University and The Alfred Hospital, Melbourne, Victoria, Australia
[37]Radiology/MRI department, MRC Cognition and Brain Sciences Unit, Cambridge, UK
[38]Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen, Göttingen, Germany
[39]Oxford University Hospitals NHS Trust, Oxford, UK
[40]Intensive Care Unit, CHU Poitiers, Potiers, France
[41]University of Manchester NIHR Biomedical Research Centre, Critical Care Directorate, Salford Royal Hospital NHS Foundation Trust, Salford, UK
[42]Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK
[43]Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium
[44]Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara, Italy
[45]Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
[46]Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
[47]Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
[48]Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
[49]Intensive Care Unit, CHR Citadelle, Liège, Belgium
[50]Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs, Hungary
[51]Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark
[52]National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, New Zealand
[53]Department of Neurology, Erasmus MC, Rotterdam, the Netherlands
[54]Department of Anesthesiology and Intensive care, University Hospital Northern Norway, Tromso, Norway
[55]Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem, Israel
[56]Fundación Instituto Valenciano de Neurorrehabilitación (FIVAN), Valencia, Spain
[57]Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotong University/school of medicine, Shanghai, China
[58]Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility, Stockholm, Sweden
[59]Emergency Department, CHU, Liège, Belgium
[60]Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia
[61]Department of Computing, Imperial College London, London, UK
[62]Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain

[63]Department of Anesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Austria
[64]Department of Public Health, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands
[65]College of Health and Medicine, Australian National University, Canberra, Australia
[66]Department of Neurosurgery, Neurosciences Centre & JPN Apex trauma centre, All India Institute of Medical Sciences, New Delhi-110029, India
[67]Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands
[68]Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
[69]Division of Psychology, University of Stirling, Stirling, UK
[70]Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital & University of Cambridge, Cambridge, UK
[71]Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
[72]Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
[73]Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford, UK
[74]Department of Intensive Care and Department of Ethics and Philosophy of Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
[75]Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden
[76]Hungarian Brain Research Program - Grant No. KTIA_13_NAP-A-II/8, University of Pécs, Pécs, Hungary
[77]Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany
[78]Cyclotron Research Center, University of Liège, Liège, Belgium
[79]Centre for Urgent and Emergency Care Research (CURE), Health Services Research Section, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
[80]Emergency Department, Salford Royal Hospital, Salford UK
[81]Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University, Cologne, Germany
[82]VP Global Project Management CNS, ICON, Paris, France
[83]Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France
[84]Department of Neurosurgery, Rambam Medical Center, Haifa, Israel
[85]Department of Anesthesiology & Intensive Care, University Hospitals Southhampton NHS Trust, Southhampton, UK
[86]Department of Translational Neuroscience, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium
[87]Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany
[88]Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK
[89]Department of Neurological Surgery, University of California, San Francisco, California, USA
[90]Department of Anesthesia & Intensive Care,M. Bufalini Hospital, Cesena, Italy
[91]Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
[92]Department of Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool, UK

[93]Department of Medical Genetics, University of Pécs, Pécs, Hungary
[94]Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara, Romania
[95]School of Medical Sciences, Örebro University, Örebro, Sweden
[96]Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
[97]Analytic and Translational Genetics Unit, Department of Medicine; Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
[98]Program in Medical and Population Genetics; The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
[99]Department of Radiology, University of Antwerp, Edegem, Belgium
[100]Department of Anesthesiology & Intensive Care, University Hospital of Grenoble, Grenoble, France
[101]Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di Padova, Padova, Italy
[102]Dept. of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands
[103]Department of Neurosurgery, Helsinki University Central Hospital
[104]Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain Injury Centre, Turku University Hospital and University of Turku, Turku, Finland
[105]Department of Anesthesiology and Critical Care, Pitié -Salpêtrière Teaching Hospital, Assistance Publique, Hôpitaux de Paris and University Pierre et Marie Curie, Paris, France
[106]Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron Research Institute, Barcelona, Spain
[107]Department of Neurosurgery, Kaunas University of technology and Vilnius University, Vilnius, Lithuania
[108]Department of Neurosurgery, Rezekne Hospital, Latvia
[109]Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University of Edinburg, Edinburgh, UK
[110]Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK
[111]Department of Physical Medicine and Rehabilitation, Oslo University Hospital/University of Oslo, Oslo, Norway
[112]Division of Orthopedics, Oslo University Hospital, Oslo, Norway
[113]Institue of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
[114]Broad Institute, Cambridge MA Harvard Medical School, Boston MA, Massachusetts General Hospital, Boston MA, USA
[115]National Trauma Research Institute, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia
[116]Department of Neurosurgery, Odense University Hospital, Odense, Denmark
[117]International Neurotrauma Research Organisation, Vienna, Austria
[118]Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
[119]Division of Biostatistics and Epidemiology, Department of Preventive Medicine, University of Debrecen, Debrecen, Hungary
[120]Department Health and Prevention, University Greifswald, Greifswald, Germany

[121]Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg, Austria
[122]Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands
[123]Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital, Odense, Denmark
[124]Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
[125]Department of Physical Medicine and Rehabilitation, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
[126]Department of Neurosurgery, University of Pécs, Pécs, Hungary
[127]Division of Neuroscience Critical Care, John Hopkins University School of Medicine, Baltimore, USA
[128]Department of Neuropathology, Queen Elizabeth University Hospital and University of Glasgow, Glasgow, UK
[129]Dept. of Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
[130]Department of Pathophysiology and Transplantation, Milan University, and Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
[131]Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå, Sweden
[132]Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital and University of Turku, Turku, Finland
[133]Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
[134]Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands
[135]Department of Neurosurgery, Kings college London, London, UK
[136]Neurologie, Neurochirurgie und Psychiatrie, Charité – Universitätsmedizin Berlin, Berlin, Germany
[137]Department of Intensive Care Adults, Erasmus MC– University Medical Center Rotterdam, Rotterdam, the Netherlands
[138]icoMetrix NV, Leuven, Belgium
[139]Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK
[140]Radiology Department, Antwerp University Hospital, Edegem, Belgium
[141]Director of Neurocritical Care, University of California, Los Angeles, USA
[142]Department of Neurosurgery, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
[143]Department of Emergency Medicine, University of Florida, Gainesville, Florida, USA
[144]Department of Neurosurgery, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
[145]VTT Technical Research Centre, Tampere, Finland
[146]Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

*Co-lead investigators: andrew.maas@uza.be (AIRM) and dkm13@cam.ac.uk (DM)

References

1. Stocchetti N, Maas AIR. Traumatic Intracranial Hypertension. N Engl J Med 2014;370(22):2121–2130; doi: 10.1056/NEJMra1208708.

2. Meyfroidt G, Bouzat P, Casaer MP, et al. Management of moderate to severe traumatic brain injury: an update for the intensivist. Intensive Care Med 2022;48(6):649–666; doi: 10.1007/s00134-022-06702-4.

3. Menon DK, Ercole A. Chapter 14 - Critical care management of traumatic brain injury. Wijdicks EFM, Kramer AH. eds. Handb Clin Neurol 2017;140(Journal Article):239–274; doi: 10.1016/B978-0-444-63600-3.00014-3.

4. Stocchetti N, Carbonara M, Citerio G, et al. Severe traumatic brain injury: targeted management in the intensive care unit. Lancet Neurol 2017;16(6):452–464; doi: 10.1016/S1474-4422(17)30118-7.

5. Hawryluk GWJ, Aguilera S, Buki A, et al. A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). Intensive Care Med 2019;45(12):1783–1794; doi: 10.1007/s00134-019-05805-9.

6. Maset AL, Marmarou A, Ward JD, et al. Pressure-volume index in head injury. J Neurosurg 1987;67(6):832–840; doi: 10.3171/jns.1987.67.6.0832.

7. Shore PM, Hand LL, Roy L, et al. Reliability and validity of the Pediatric Intensity Level of Therapy (PILOT) scale: A measure of the use of intracranial pressure–directed therapies. Crit Care Med 2006;34(7):1981; doi: 10.1097/01.CCM.0000220765.22184.ED.

8. Maas AIR, Harrison-Felix CL, Menon D, et al. Standardizing Data Collection in Traumatic Brain Injury. J Neurotrauma 2011;28(2):177–187; doi: 10.1089/neu.2010.1617.

9. Zuercher P, Groen JL, Aries MJH, et al. Reliability and Validity of the Therapy Intensity Level Scale: Analysis of Clinimetric Properties of a Novel Approach to Assess Management of Intracranial Pressure in Traumatic Brain Injury. J Neurotrauma 2016;33(19):1768–1774; doi: 10.1089/neu.2015.4266.

10. Robba C, Graziano F, Guglielmi A, et al. Treatments for intracranial hypertension in acute brain-injured patients: grading, timing, and association with outcome. Data from the SYNAPSE-ICU study. Intensive Care Med 2023;49(1):50–61; doi: 10.1007/s00134-022-06937-1.

1012 11. Huijben JA, Wiegers EJA, Lingsma HF, et al. Changing care pathways and
1013 between-center practice variations in intensive care for traumatic brain injury across
1014 Europe: a CENTER-TBI analysis. Intensive Care Med 2020;46(5):995–1004; doi:
1015 10.1007/s00134-020-05965-z.

1016 12. Huijben JA, Dixit A, Stocchetti N, et al. Use and impact of high intensity
1017 treatments in patients with traumatic brain injury across Europe: a CENTER-TBI
1018 analysis. Crit Care 2021;25(1):78; doi: 10.1186/s13054-020-03370-y.

1019 13. Bhattacharyay S, Caruso PF, Åkerlund C, et al. Mining the contribution of
1020 intensive care clinical course to outcome after traumatic brain injury. Npj Digit Med
1021 2023;6(1):154; doi: 10.1038/s41746-023-00895-8.

1022 14. Zoerle T, Birg T, Carbonara M, et al. Accuracy of Manual Intracranial Pressure
1023 Recording Compared to a Computerized High-Resolution System: A CENTER-TBI
1024 Analysis. Neurocrit Care 2023; doi: 10.1007/s12028-023-01697-2.

1025 15. Maas AIR, Menon DK, Manley GT, et al. Traumatic brain injury: progress and
1026 challenges in prevention, clinical care, and research. Lancet Neurol
1027 2022;21(11):1004–1060; doi: 10.1016/S1474-4422(22)00309-X.

1028 16. Cnossen MC, Huijben JA, van der Jagt M, et al. Variation in monitoring and
1029 treatment policies for intracranial hypertension in traumatic brain injury: a survey in 66
1030 neurotrauma centers participating in the CENTER-TBI study. Crit Care
1031 2017;21(1):233; doi: 10.1186/s13054-017-1816-9.

1032 17. Avila ML, Stinson J, Kiss A, et al. A critical review of scoring options for clinical
1033 measurement tools. BMC Res Notes 2015;8(1):612; doi: 10.1186/s13104-015-1561-
1034 6.

1035 18. Maas AIR, Menon DK, Steyerberg EW, et al. Collaborative European
1036 NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): A
1037 Prospective Longitudinal Observational Study. Neurosurgery 2015;76(1):67–80; doi:
1038 10.1227/NEU.0000000000000575.

1039 19. Steyerberg EW, Wiegers E, Sewalt C, et al. Case-mix, care pathways, and
1040 outcomes in patients with traumatic brain injury in CENTER-TBI: a European
1041 prospective, multicentre, longitudinal, cohort study. Lancet Neurol 2019;18(10):923–
1042 934; doi: 10.1016/S1474-4422(19)30232-7.

1043 20. Doiron D, Marcon Y, Fortier I, et al. Software Application Profile: Opal and Mica:
1044 open-source software solutions for epidemiological data management, harmonization
1045 and dissemination. Int J Epidemiol 2017;46(5):1372–1378; doi: 10.1093/ije/dyx180.

1046 21. Zeiler FA, Ercole A, Cabeleira M, et al. Patient-specific ICP Epidemiologic
1047 Thresholds in Adult Traumatic Brain Injury: A CENTER-TBI Validation Study. J
1048 Neurosurg Anesthesiol 2021;33(1):28–38; doi: 10.1097/ANA.0000000000000616.

1049 22. Marshall LF, Marshall SB, Klauber MR, et al. The diagnosis of head injury
1050 requires a classification based on computed axial tomography. J Neurotrauma 1992;9
1051 Suppl 1:S287-292.

1052 23. Teasdale G, Maas A, Lecky F, et al. The Glasgow Coma Scale at 40 years:
1053 standing the test of time. The LancetNeurology 2014;13(8):844–854; doi:
1054 10.1016/S1474-4422(14)70120-6.

1055 24. Ercole A, Dixit A, Nelson DW, et al. Imputation strategies for missing baseline
1056 neurological assessment covariates after traumatic brain injury: A CENTER-TBI
1057 study. PLoS ONE 2021;16(8):e0253425.

1058 25. McMillan T, Wilson L, Ponsford J, et al. The Glasgow Outcome Scale - 40 years
1059 of application and refinement. Nat Rev Neurol 2016;12(8):477–485; doi:
1060 10.1038/nrneurol.2016.89.

1061 26. Kunzmann K, Wernisch L, Richardson S, et al. Imputation of Ordinal Outcomes:
1062 A Comparison of Approaches in Traumatic Brain Injury. J Neurotrauma
1063 2021;38(4):455–463; doi: 10.1089/neu.2019.6858.

1064 27. Bhattacharyay S, Milosevic I, Wilson L, et al. The leap to ordinal: Detailed
1065 functional prognosis after traumatic brain injury with a flexible modelling approach.
1066 PLoS ONE 2022;17(7):e0270973; doi: 10.1371/journal.pone.0270973.

1067 28. Boateng GO, Neilands TB, Frongillo EA, et al. Best Practices for Developing and
1068 Validating Scales for Health, Social, and Behavioral Research: A Primer. Front Public
1069 Health 2018;6:149; doi: 10.3389/fpubh.2018.00149.

1070 29. Bakdash JZ, Marusich LR. Repeated Measures Correlation. Front Psychol
1071 2017;8:456; doi: 10.3389/fpsyg.2017.00456.

1072 30. van Buuren S, Groothuis-Oudshoorn CGM. mice: Multivariate Imputation by
1073 Chained Equations in R. J Stat Softw 2011;45(3):1–67; doi: 10.18637/jss.v045.i03.

1074 31. Gravesteijn BY, Sewalt CA, Venema E, et al. Missing Data in Prediction
1075 Research: A Five-Step Approach for Multiple Imputation, Illustrated in the CENTER-
1076 TBI Study. J Neurotrauma 2021;38(13):1842–1857; doi: 10.1089/neu.2020.7218.

1077 32. Honaker J King, G, Blackwell,M. Amelia II: A Program for Missing Data. J Stat
1078 Softw 2011;45(7); doi: 10.18637/jss.v045.i07.

1079 33. Beqiri E, Smielewski P, Robba C, et al. Feasibility of individualised severe
1080 traumatic brain injury management using an automated assessment of optimal
1081 cerebral perfusion pressure: the COGiTATE phase II study protocol. BMJ Open
1082 2019;9(9):e030727; doi: 10.1136/bmjopen-2019-030727.

1083 34. Tas J, Beqiri E, van Kaam RC, et al. Targeting Autoregulation-Guided Cerebral
1084 Perfusion Pressure after Traumatic Brain Injury (COGiTATE): A Feasibility

1085 Randomized Controlled Clinical Trial. J Neurotrauma 2021;38(20):2790–2800; doi:
1086 10.1089/neu.2021.0197.

1087 35. van Erp IAM, van Essen TA, Fluiter K, et al. Safety and efficacy of C1-inhibitor in
1088 traumatic brain injury (CIAO@TBI): study protocol for a randomized, placebo-
1089 controlled, multi-center trial. Trials 2021;22(1):874; doi: 10.1186/s13063-021-05833-
1090 1.

1091 36. Schreiber JB. Issues and recommendations for exploratory factor analysis and
1092 principal component analysis. Res Soc Adm Pharm 2021;17(5):1004–1011; doi:
1093 10.1016/j.sapharm.2020.07.027.

1094 37. Clark D, Joannides A, Adeleye AO, et al. Casemix, management, and mortality of
1095 patients receiving emergency neurosurgery for traumatic brain injury in the Global
1096 Neurotrauma Outcomes Study: a prospective observational cohort study. Lancet
1097 Neurol 2022;21(5):438–449; doi: 10.1016/S1474-4422(22)00037-0.

1098 38. Okonkwo DO, Shutter LA, Moore C, et al. Brain Oxygen Optimization in Severe
1099 Traumatic Brain Injury Phase-II: A Phase II Randomized Trial*. Crit Care Med
1100 2017;45(11):1907; doi: 10.1097/CCM.0000000000002619.

1101 39. Hutchinson PJ, Jalloh I, Helmy A, et al. Consensus statement from the 2014
1102 International Microdialysis Forum. Intensive Care Med 2015;41(9):1517–1528; doi:
1103 10.1007/s00134-015-3930-y.

1104 40. Yokobori S, Yokota H. Targeted temperature management in traumatic brain
1105 injury. J Intensive Care 2016;4(1):28; doi: 10.1186/s40560-016-0137-4.

1106 41. Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of Decompressive
1107 Craniectomy for Traumatic Intracranial Hypertension. N Engl J Med
1108 2016;375(12):1119–1130; doi: 10.1056/NEJMoa1605215.

1109



Fig. 1. Flow diagram for patient enrolment and validation population assignment. Abbreviations: CENTER-TBI=Collaborative European NeuroTrauma Effectiveness Research in TBI, ICP=intracranial pressure, ICP_{EH}=end-hour ICP, ICP_{HR}=high-resolution ICP, ICU=intensive care unit, TBI=traumatic brain injury, TIL=Therapy Intensity Level scale,[8,9] WLST=withdrawal of life-sustaining therapies.



Fig. 2. Distributions of TIL and alternative scales. Abbreviations: ICU=intensive care unit, PILOT=Paediatric Intensity Level of Therapy scale,[7] TIL=Therapy Intensity Level scale,[8,9] TIL$^{(1987)}$=original Therapy Intensity Level scale published in 1987,[6] TIL$^{(Basic)}$=condensed TIL scale,[8] uwTIL=unweighted TIL scale in which sub-item scores are replaced by the ascending rank index within the item. The numeric definition of each scale is listed in Table 1. (**A**) Distributions of maximum scores of TIL (i.e., TIL$_{max}$) and alternative scales (i.e., uwTIL$_{max}$, TIL$^{(Basic)}_{max}$, PILOT$_{max}$, and TIL$^{(1987)}_{max}$) over the first week of ICU stay. (**B**) Distribution of median scores of TIL (i.e., TIL$_{median}$) and alternative scales (i.e., uwTIL$_{median}$, TIL$^{(Basic)}_{median}$, PILOT$_{median}$, and TIL$^{(1987)}_{median}$) over the first week of ICU stay. (**C**) Distributions of daily scores of TIL (i.e., TIL$_{24}$) and alternative scales (i.e., uwTIL$_{24}$, TIL$^{(Basic)}_{24}$, PILOT$_{24}$, and TIL$^{(1987)}_{24}$) over the first week of ICU stay.



Fig. 3. Associations of TIL and alternative scales with other clinical measures. Abbreviations: Day_{ICU}=variable representing day (from 1 to 7) of ICU stay, EH=end-hour, CPP=cerebral perfusion pressure, GCS=Glasgow Coma Scale at ICU admission, GOSE=Glasgow Outcome Scale–Extended at six months post-injury, HR=high-resolution, ICP=intracranial pressure, ICU=intensive care unit, PILOT=Paediatric Intensity Level of Therapy scale,[7] Pr(GOSE>•)="probability of GOSE greater than • at six months post-injury" as previously calculated from the first 24 hours of admission,[27] TIL=Therapy Intensity Level scale,[8,9] $TIL^{(1987)}$=original Therapy Intensity Level scale published in 1987,[6] $TIL^{(Basic)}$=condensed TIL scale,[8] uwTIL=unweighted TIL scale in which sub-item scores are replaced by the ascending rank index

within the item. The numeric definition of each scale is listed in Table 1, and the calculation of daily (e.g., TIL_{24}), maximum (e.g., TIL_{max}), and median (e.g., TIL_{median}) scores are described in the Methods. The bars represent 95% confidence intervals derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value imputations. (**A**) Spearman's correlation coefficients (ρ) between maximum scale scores over first week of ICU stay (i.e., TIL_{max}, $uwTIL_{max}$, $TIL^{(Basic)}_{max}$, $PILOT_{max}$, and $TIL^{(1987)}_{max}$) and other clinical measures. (**B**) Spearman's correlation coefficients (ρ) between median scale scores over first week of ICU stay (i.e., TIL_{median}, $uwTIL_{median}$, $TIL^{(Basic)}_{median}$, $PILOT_{median}$, and $TIL^{(1987)}_{median}$) and other clinical measures. (**C**) Repeated measures correlation coefficients (r_{rm}, from -1 to 1) are interpreted as the strength and direction of association between two variables after accounting for inter-patient variation. (**D**) Linear mixed effects model coefficients (β_{LMER}) are interpreted as the expected difference in dependent variable (e.g., EH ICP_{24}) per unit increase of daily scale score (e.g., TIL_{24}) after accounting for time since ICU admission (i.e., Day_{ICU}) and inter-patient variation.



Fig 4. Distributions of daily intracranial pressure and cerebral perfusion pressure means per daily TIL score. Abbreviations: CPP=cerebral perfusion pressure, CPP_{24}=mean CPP over calendar day, Day_{ICU}=variable representing day (from 1 to 7) of ICU stay, EH=end-hour, HR=high-resolution, ICP=intracranial pressure, ICP_{24}=mean ICP over calendar day, TIL=Therapy Intensity Level scale,[8,9] TIL_{24}=TIL score of calendar day, TIL-ICP_{EH}=end-hour ICP sub-population, TIL-ICP_{HR}=high-resolution ICP sub-population. The values in each panel are the linear mixed effects model coefficients (β_{LMER}) of TIL_{24} with 95% confidence intervals derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value imputations. The width of violin plots is scaled for each population, but the width of the points inside them demonstrates relative frequency across the populations. The violin plots do not encompass outliers based on 1.5 times the interquartile range. (**A**) Distributions of ICP_{24} vs. TIL_{24} for both sub-populations. (**B**) Distributions of CPP_{24} vs. TIL_{24} for both sub-populations.



Fig 5. Discrimination of refractory intracranial hypertension status by TIL and alternative scale summary scores. Abbreviations: AUC=area under the receiver operating characteristic curve, EH=end-hour, HR=high-resolution, ICP=intracranial pressure, ICP_{max}=maximum calendar day mean of ICP over first week of ICU stay, ICP_{median}=median calendar day mean of ICP over first week of ICU stay, ICU=intensive care unit, PILOT=Paediatric Intensity Level of Therapy scale,[7] TIL=Therapy Intensity Level scale,[8,9] $TIL^{(1987)}$=original Therapy Intensity Level scale published in 1987,[6] $TIL^{(Basic)}$=condensed TIL scale,[8] uwTIL=unweighted TIL scale in which sub-item scores are replaced by the ascending rank index within the item. The 95% confidence intervals of AUC were derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value imputations. (**A**) Distributions of maximum scores of TIL (i.e., TIL_{max}) and alternative scales (i.e., $uwTIL_{max}$, $TIL^{(Basic)}_{max}$, $PILOT_{max}$, and $TIL^{(1987)}_{max}$) stratified by refractory intracranial hypertension status. The horizontal black line segments represent the thresholds which maximised the sum of sensitivity and specificity for each scale. (**B**) Distributions of median scores of TIL (i.e., TIL_{median}) and alternative scales (i.e., $uwTIL_{median}$, $TIL^{(Basic)}_{median}$, $PILOT_{median}$, and $TIL^{(1987)}_{median}$) stratified by refractory intracranial hypertension status. The horizontal black line segments represent the thresholds which maximised the sum of sensitivity and specificity for each scale. (**C**) Receiver operating characteristic curve of refractory intracranial hypertension detection with TIL_{max}. The threshold which maximised the sum of sensitivity and specificity is highlighted with the dark red circle. (**D**) Receiver operating characteristic curve of refractory intracranial hypertension detection with TIL_{median}. The threshold which maximised the sum of sensitivity and specificity is highlighted with the dark red circle.



Fig 6. Association of TIL component items with TIL_{24} and other study measures. Abbreviations: CPP=cerebral perfusion pressure, CPP_{24}=mean CPP over calendar day, CSF=cerebrospinal fluid, EH=end-hour, HR=high-resolution, ICP=intracranial pressure, ICP_{24}=mean ICP over calendar day, ICU=intensive care unit, TIL=Therapy Intensity Level scale,[8,9] TIL_{24}=TIL score of calendar day. The 95% confidence intervals of r_{rm} and β_{LMER} values were derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value

imputations. (**A**) Median component score of each ICP-treatment modality (Table 1) per each TIL_{24} score. The histogram under the *x*-axis represents the relative frequency and count of each TIL_{24} score in the population, and diagonal dashed line represents the TIL_{24} score on both axes. If the sum of median item scores does not equal the corresponding TIL_{24} score, this can be interpreted as high variability in the combination of simultaneously applied therapies at that TIL_{24} score. (**B**) The repeated measures correlation coefficients (r_{rm}, from -1 to 1) are interpreted as the strength and direction of association between two variables after accounting for inter-patient variation. The component score of each item (Table 1, *x*-axis) was subtracted from the TIL_{24} score (top row on *y*-axis) before calculating their r_{rm} values. (**C**) Linear mixed effects model coefficients (β_{LMER}) are interpreted as the expected difference in the dependent variable (*y*-axis) associated with the given TIL_{24} sub-item treatment (Table 1) after accounting for all other TIL_{24} sub-items, time since ICU admission, and inter-patient variation.



Fig 7. Relationship between TIL and TIL$^{(Basic)}$. Abbreviations: AUC=area under the receiver operating characteristic curve, ICU=intensive care unit, TIL=Therapy Intensity Level scale,[8,9] TIL$^{(Basic)}$=condensed TIL scale.[8] The numeric definition of each scale is listed in Table 1, and the calculation of daily (e.g., TIL_{24}), maximum (e.g., TIL_{max}), and median (e.g., TIL_{median}) scores are described in the Methods. The 95% confidence intervals of information coverage were derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value imputations. (**A**) Distribution of corresponding $TIL^{(Basic)}_{24}$ scores per each TIL_{24} score. The values in each cell represent the percent of assessments at a given TIL_{24} score (i.e., column) corresponding to a $TIL^{(Basic)}_{24}$ score (i.e., row). The vertical, dark red lines represent cut-offs across which the median corresponding $TIL^{(Basic)}_{24}$ score per TIL_{24} score changes. (**B**) Distribution of corresponding TIL_{24} scores per each $TIL^{(Basic)}_{24}$ score. The width of violin plots is scaled for each $TIL^{(Basic)}_{24}$ score, but the width of the points inside them demonstrates relative frequency across the $TIL^{(Basic)}_{24}$ scores. The grey, shaded zones represent the range of TIL_{24} scores with corresponding median $TIL^{(Basic)}_{24}$ scores on the *x*-axis, as determined in panel (A). (**C**) The information of TIL_{24}, TIL_{max}, and TIL_{median} covered by $TIL^{(Basic)}_{24}$, $TIL^{(Basic)}_{max}$, and $TIL^{(Basic)}_{median}$, respectively. Information coverage is defined as the mutual information of TIL_{24} and $TIL^{(Basic)}_{24}$ (or TIL_{max} and $TIL^{(Basic)}_{max}$ or TIL_{median} and $TIL^{(Basic)}_{median}$) divided by the entropy of TIL_{24} (or TIL_{max} or TIL_{median}).

Table 1. Scoring configurations for TIL and alternative scales

ICP-treatment modality	Item	TIL		uwTIL		TIL(Basic)a	PILOTb		TIL(1987)b	
	Sub-item	**Score**	**Max**	Score	Max	Score[a]	Score	Max	Score	Max
Positioning	Head elevation for ICP control or nursed flat (180°) for CPP management	1	1	1	1	1	–	–	–	–
Sedation and neuromuscular blockade	Sedation		5		3			5		4
	Low dose sedation (as required for mechanical ventilation)	1		1		1	1		1	
	Higher dose sedation for ICP control (but not aiming for burst suppression)	2		2		2	1		1	
	High dose propofol or barbiturates for ICP control (metabolic suppression)	5		3		4	5		4	
	Neuromuscular blockade (paralysis)	3	3	1	1	–	2	2	1	1
CSF drainage	CSF drainage volume		3		2			5		2
	Low (<120 ml/24h)	2		1		2	4		1	
	High (≥120 ml/24h)	3		2		3	5		2	
CPP management	Fluid loading for maintenance of cerebral perfusion	1	1	1	1	2	–	–	–	–
	Vasopressor therapy required for management of cerebral perfusion	1	1	1	1	2	2	2	–	–
Ventilatory management	Hypocapnia for ICP control (P_aCO_2 [mmHg])		4		3			4		2
	Mild ($35 \leq P_aCO_2 < 40$)	1		1		2	1		1	
	Moderate ($30 \leq P_aCO_2 < 35$)	2		2		3	2		1	
	Intensive ($P_aCO_2 < 30$)	4		3		4	4		2	
Hyperosmolar therapy	Mannitol administration		3		2			3		6
	≤2g/kg/24h	2		1		2	2		3	
	>2g/kg/24h	3		2		3	3		6	
	Hypertonic saline administration		3		2			3	–	–
	≤0.3g/kg/24h	2		1		2	3			
	>0.3g/kg/24h	3		2		3	3			
Temperature control	Temperature control (T [°C])		5		3			5	–	–
	Fever control (>38 or spontaneous <34.5)	1		1			1			
	Cooling for ICP control (≥35)	2		2		3	3			
	Hypothermia (<35)	5		3		4	5			

Surgery for intracranial hypertension	Intracranial operation for progressive mass lesion, NOT scheduled on admission	4	4	1	1	4	4	4	–	–
	Decompressive craniectomy	5	5	1	1	4	5	5	–	–
Maximum total possible score			38		21	4		38		15

Abbreviations: CPP=cerebral perfusion pressure, CSF=cerebrospinal fluid, ICP=intracranial pressure, P_aCO_2=partial pressure of carbon dioxide in arterial blood, PILOT=Paediatric Intensity Level of Therapy scale,[7] T=body temperature in degrees Celsius, TIL=Therapy Intensity Level scale,[8,9] $TIL^{(1987)}$=original Therapy Intensity Level scale published in 1987,[6] $TIL^{(Basic)}$=condensed TIL scale,[8] uwTIL=unweighted TIL scale in which sub-item scores are replaced by the ascending rank index within the item.

The TIL scale was developed by Maas *et al*.[8] For each calendar day, the highest score for each item was summed to derive the TIL score.

[a]$TIL^{(Basic)}$ is the maximum score (up to 4) among all administered sub-items over the calendar day. If no sub-items are administered on a given day, $TIL^{(Basic)}$=0.

[b]PILOT scale[7] and $TIL^{(1987)}$ scale[6] scoring configurations have been adapted with minor adjustments to fit the items of TIL with a daily assessment frequency.

Table 2. Summary characteristics of study validation populations

Summary characteristic	TIL validation population			
	Overall (*n*=873, 52 centres)	**TIL-ICP$_{EH}$** (*n*=837, 51 centres)	**TIL-ICP$_{HR}$** (*n*=259, 21 centres)	***p*-value**[c]
Age [years]	47 (29–62)	47 (29–62)	48 (30–62.5)	0.303
Sex: Female	222 (25%)	213 (25%)	55 (21%)	0.078
Baseline GCS (*n*[a]=822)				0.554
Mild [13–15]	122 (15%)	115 (15%)	38 (16%)	
Moderate [9–12]	139 (17%)	133 (17%)	36 (15%)	
Severe [3–8]	561 (68%)	539 (68%)	170 (70%)	
Marshall CT (*n*[a]=710)				0.278
No visible pathology (I)	17 (2%)	16 (2%)	6 (3%)	
Diffuse injury II	264 (37%)	248 (36%)	75 (35%)	
Diffuse injury III	93 (13%)	89 (13%)	22 (10%)	
Diffuse injury IV	16 (2%)	16 (2%)	3 (1%)	
Mass lesion (V & VI)	320 (45%)	312 (46%)	107 (50%)	
Six-month GOSE (*n*[a]=761)				0.329
(1) Death	199 (26%)	195 (26%)	54 (23%)	
(2 or 3) Vegetative or lower SD	182 (24%)	181 (25%)	63 (27%)	
(4) Upper SD	70 (9%)	66 (9%)	22 (9%)	
(5) Lower MD	122 (16%)	117 (16%)	44 (19%)	
(6) Upper MD	74 (10%)	71 (10%)	23 (10%)	
(7) Lower GR	56 (7%)	52 (7%)	14 (6%)	
(8) Upper GR	58 (8%)	55 (7%)	13 (6%)	
Baseline functional prognosis[b] [%] (*n*[a]=749)				
Pr(GOSE>1)	84.7 (63.5–94.9)	84.1 (62.1–94.7)	83.8 (66.9–94.0)	0.664
Pr(GOSE>3)	53.9 (29.9–76.0)	53.1 (29.2–75.0)	52.4 (33.9–71.1)	0.287
Pr(GOSE>4)	39.6 (20.6–59.6)	38.9 (19.8–58.3)	38.1 (22.6–54.6)	0.154
Pr(GOSE>5)	21.1 (10.2–36.8)	20.7 (10.0–36.0)	19.3 (10.5–30.1)	0.037
Pr(GOSE>6)	12.4 (5.9–20.8)	12.0 (5.8–19.9)	10.9 (5.8–17.2)	0.009
Pr(GOSE>7)	4.8 (2.2–9.2)	4.7 (2.2–9.1)	5.3 (2.2–8.5)	0.415
TIL$_{max}$	10 (6–14)	10 (6–14)	10 (6–14)	0.577
TIL$_{median}$	5 (3–10)	5 (3–10)	5 (4–10)	0.826
TIL$_{24}$ scores				
Day 1 (*n*[a]=852)	7 (4–11)	7 (4–11)	7 (5–10)	0.134
Day 2 (*n*[a]=839)	6 (4–10)	6 (4–10)	6 (4–10)	0.860
Day 3 (*n*[a]=819)	6 (3–9)	6 (3–9)	6 (4–9)	0.926
Day 4 (*n*[a]=787)	6 (3–10)	6 (3–10)	5 (4–10)	0.372
Day 5 (*n*[a]=761)	5 (3–10)	5 (3–10)	5 (3–10)	0.941
Day 6 (*n*[a]=733)	5 (2–9)	5 (2.5–9)	5 (3–10)	0.337
Day 7 (*n*[a]=709)	5 (2–9)	4 (2–9)	5 (2–9)	0.425

Abbreviations: Baseline GCS=Glasgow Coma Scale at ICU admission, from 3 to 15, GOSE=GOS–Extended, GR=good recovery, ICP=intracranial pressure, ICP$_{EH}$=end-hour ICP, ICP$_{HR}$=high-resolution ICP, Marshall CT=Marshall computerised tomography classification, MD=moderate disability, Pr(GOSE>•)="probability of GOSE greater than • at six months post-injury" as previously calculated from the first 24 hours of admission,[27] SD=severe disability, TIL=Therapy Intensity Level scale, TIL$_{24}$=TIL score of calendar day in ICU, TIL$_{max}$=maximum TIL$_{24}$ over first week of ICU stay, TIL$_{median}$=median TIL$_{24}$ over first week of ICU stay. Data are median (IQR) for numeric characteristics and *n* (% of column group) for categorical characteristics, unless

otherwise indicated. Units or numerical definitions of characteristics are provided in square brackets.

[a]Limited sample size of non-missing values for characteristic.

[b]Ordinal functional outcome prognostic scores were calculated through tokenised embedding of all clinical information in the first 24 hours of ICU stay, as described previously.[27]

[c]*p*-values, comparing patients in TIL-ICP_{HR} sub-population to those not in TIL-ICP_{HR} sub-population, are derived from with Welch's *t*-test for numeric variables and χ^2 contingency table test for categorical variables.

Table 3. Optimised ranges for TIL categorisation

Category	Derived ranges	Performance (95% confidence intervals)			Case counts[c]		Previously proposed ranges[d]
		Sensitivity	Specificity	Accuracy	No	Yes	
Refractory intracranial hypertension[a]	TIL_{max}≥14	68% (62–74%)	79% (77–81%)	77% (75–79%)	707	157	TIL_{max}≥11
	TIL_{median}≥7.5	81% (77–87%)	72% (70–75%)	74% (72–76%)			–
Day of surgical ICP control[b]	TIL_{24}≥9	87% (83–91%)	74% (72–76%)	76% (74–77%)	4916	585	–
$TIL^{(Basic)}_{24}$				72% (70–73%)			
(1) Basic ICU care	1≤TIL_{24}≤2				4932	568	1≤TIL_{24}≤3
(2) Mild	3≤TIL_{24}≤6				3294	2206	4≤TIL_{24}≤7
(3) Moderate	7≤TIL_{24}≤8				4709	791	8≤TIL_{24}≤10
(4) Extreme	TIL_{24}≥9				3919	1581	TIL_{24}≥11

Abbreviations: ICP=intracranial pressure, ICU=intensive care unit, TIL=Therapy Intensity Level scale,[8,9] $TIL^{(Basic)}$=condensed TIL scale.[8] The numeric definition of each scale is listed in Table 1, and the calculation of daily (e.g., TIL_{24}), maximum (e.g., TIL_{max}), and median (e.g., TIL_{median}) scores is described in the Methods. The 95% confidence intervals of performance metrics were derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value imputations.

[a]Refractory intracranial hypertension was defined as recurrent, sustained (i.e., of at least ten minutes) increases of ICP above 20 mmHg despite medical ICP management during ICU stay. This information was recorded by attending physicians in patient discharge summaries.

[b]If a decompressive craniectomy was performed as a last resort for refractory intracranial hypertension, each of the days following the operation were also considered days of surgical ICP control.

[c]For refractory intracranial hypertension, case counts represent the number of patients (with non-missing values) without (i.e., No) and with (i.e., Yes) refractory intracranial hypertension. For day of surgical ICP control and $TIL^{(Basic)}_{24}$, case counts represent the number of non-missing TIL assessments not in (i.e., No) and in (i.e., Yes) the given category.

[d]Thresholds were previously proposed by the interagency panel which developed TIL based on expert opinion.[8]